This may be due to reduced fasting and prandial glucose levels and decreased HbA(1)c levels.[35] When vildagliptin and metformin are used in patients with T2DM for more than 52 weeks, beta-cell function is improved along with postmeal insulin sensitivity.[18] Initial clinical trial indicates that vildagliptin is an important oral treatment option for weight neutral, glycemic control when combined with metformin.[47]. Here, INS is linked to type 2 diabetes mellitus.